Therapeutic efficacy of tranexamic acid on traumatic brain injury: a systematic review and meta-analysis

Scand J Trauma Resusc Emerg Med. 2024 Mar 7;32(1):18. doi: 10.1186/s13049-024-01188-z.

Abstract

Objective: Tranexamic acid (TXA) demonstrates therapeutic efficacy in the management of traumatic brain injury (TBI). The objective of this systematic review and meta-analysis was to evaluate the safety and effectiveness of TXA in patients with TBI.

Methods: The databases, namely PubMed, Embase, Web of Science, and Cochrane Library databases, were systematically searched to retrieve randomized controlled trials (RCTs) investigating the efficacy of TXA for TBI from January 2000 to November 2023.

Results: The present meta-analysis incorporates ten RCTs. Compared to the placebo group, administration of TXA in patients with TBI resulted in a significant reduction in mortality (P = 0.05), hemorrhage growth (P = 0.03), and volume of hemorrhage growth (P = 0.003). However, no significant impact was observed on neurosurgery outcomes (P = 0.25), seizure occurrence (P = 0.78), or pulmonary embolism incidence (P = 0.52).

Conclusion: The administration of TXA is significantly associated with reduced mortality and hemorrhage growth in patients suffering from TBI, while the need of neurosurgery, seizures, and incidence of pulmonary embolism remains comparable to that observed with placebo.

Keywords: Meta-analysis; Therapeutic efficacy; Tranexamic acid; Traumatic brain injury.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Antifibrinolytic Agents* / therapeutic use
  • Brain Injuries, Traumatic* / complications
  • Brain Injuries, Traumatic* / drug therapy
  • Hemorrhage / drug therapy
  • Humans
  • Pulmonary Embolism* / complications
  • Pulmonary Embolism* / drug therapy
  • Tranexamic Acid* / therapeutic use

Substances

  • Tranexamic Acid
  • Antifibrinolytic Agents